Scott Huntington, MD
Hematology & Oncology · New Haven, CTNPI 1982847588
Payments from drug & device makers
Across 212 payments — averaging $3356.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$120K
- Beigene, Ltd.$112K
- Eli Lilly$71K
- Agios Pharmaceuticals, Inc.$68K
- TG Therapeutics, Inc.$67K
- Bristol Myers Squibb$67K
- plus $207K from 19 others
Across 14 payments — averaging $1743.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$19K
- AbbVie$5K
- Bristol Myers Squibb$476
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 15 | $120,252 |
| Beigene, Ltd. | 3 | $112,206 |
| Eli Lilly | 14 | $70,555 |
| Agios Pharmaceuticals, Inc. | 19 | $67,805 |
| TG Therapeutics, Inc. | 53 | $67,448 |
| Bristol Myers Squibb | 4 | $66,751 |
| Beigene USA, Inc. | 5 | $42,920 |
| AbbVie | 14 | $36,777 |
| Merck | 8 | $29,890 |
| Genentech USA, Inc. | 16 | $23,979 |
| AstraZeneca | 13 | $16,137 |
| Pharmacyclics LLC, An Abbvie Company | 9 | $9,702 |
| E.r. Squibb & Sons, L.L.C. | 1 | $9,398 |
| Bayer | 7 | $8,549 |
| Janssen Scientific Affairs, LLC | 6 | $8,105 |
| Seagen Inc. | 9 | $7,216 |
| Ipsen Biopharmaceuticals, Inc | 1 | $3,450 |
| ADC Therapeutics America, Inc. | 2 | $2,472 |
| Epizyme, Inc. | 1 | $2,050 |
| Beone Medicines USA, Inc. | 2 | $1,836 |
| F. Hoffmann-la Roche AG | 1 | $1,681 |
| Novartis | 1 | $1,310 |
| Astrazeneca UK Limited | 5 | $798 |
| Pfizer | 2 | $214 |
| Adaptive Biotechnologies Corporation | 1 | $156 |
How this compares
$711,658 in reported general payments places this provider in the 85th percentile of 163 hematology & oncology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in New Haven
- Amer ZeidanNew Haven$15.5M
- Nataliya UbohaNew Haven$13.3M
- Michael CecchiniNew Haven$7.8M
- Tarsheen SethiNew Haven$2.6M
- Terri ParkerNew Haven$2.4M
- Iris IsufiNew Haven$2.1M
- Walid ShaibNew Haven$1.9M
- Melinda YushakNew Haven$1.7M
- Shalin KothariNew Haven$421K
- Maximilian StahlNew Haven$240K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.